Truist analyst David MacDonald lowered the firm's price target on Community Health to $3 from $3.50 and keeps a Hold rating on the shares after its Q1 results. Adjusted EBITDA landed below consensus and volumes were modestly negative across the board, though the management continues to target low single-digit growth in 2026, the analyst tells investors in a research note.
